SCHEMBL6288738

SCHEMBL6288738

CC(C(=O)O)c1cccc(OCBr)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 6/20 0.65
AKR1C3 P42330 5/20 0.52
AKR1C2 P52895 5/20 0.52
PTGS2 P35354 8/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
MAPT P10636 2/20 0.50
CXCR1 P25024 2/20 0.50
CXCR2 P25025 2/20 0.50
KDM4E B2RXH2 2/20 0.50
ALDH1A1 P00352 2/20 0.50
LMNA P02545 2/20 0.50
SLC22A6 Q4U2R8 2/20 0.50
HSD17B10 Q99714 2/20 0.50
RECQL P46063 1/20 0.50
CYP3A4 P08684 1/20 0.50
HPGD P15428 1/20 0.50
MAPK1 P28482 1/20 0.50
PMP22 Q01453 1/20 0.50
CXCL8 P10145 1/20 0.50
THPO P40225 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4128458 0.88 PTGS1 (0.61) PTGS1AKR1C3AKR1C2PTGS2SMN1; SMN2
SCHEMBL6513465 0.87 PTGS1 (0.60) PTGS1AKR1C3AKR1C2PTGS2SMN1; SMN2
SCHEMBL3674440 0.86 AKR1C3 (0.70) PTGS1AKR1C3AKR1C2PTGS2SMN1; SMN2
SCHEMBL28133951 0.84 PTGS1 (0.65) PTGS1AKR1C3AKR1C2PTGS2SMN1; SMN2
SCHEMBL4740646 0.83 PTGS1 (0.63) PTGS1AKR1C3AKR1C2PTGS2SMN1; SMN2
SCHEMBL3673447 0.83 PTGS1 (0.63) PTGS1AKR1C3AKR1C2PTGS2SMN1; SMN2
SCHEMBL2745203 0.82 PTGS1 (0.58) PTGS1AKR1C3AKR1C2PTGS2SMN1; SMN2
SCHEMBL954605 0.82 PTGS1 (0.58) PTGS1AKR1C3AKR1C2PTGS2SMN1; SMN2
SCHEMBL3668050 0.82 PTGS1 (0.61) PTGS1AKR1C3AKR1C2PTGS2SMN1; SMN2
SCHEMBL2986567 0.82 ALOX5 (0.67) PTGS1PTGS2SMN1; SMN2MAPTCXCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6838584-B2 Estrogen receptor modulators MERCK & CO., INC. (US) 2005-01-04 US disclosed
US-20040162304-A1 Estrogen receptor modulators MERCK & CO., INC. 2004-08-19 US disclosed
EP-1387821-A2 ESTROGEN RECEPTOR MODULATORS Merck & Co., Inc. (US) 2004-02-11 EP disclosed
WO-2002091993-A2 ESTROGEN RECEPTOR MODULATORS MERCK & CO., INC. (US) 2002-11-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162304-A1 Estrogen receptor modulators ESRRA, GPER1, ESRRB PTGS1 234/4885AKR1C3 649/4885AKR1C2 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.